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INTRODUCTION
Diabetes mellitus is a common endocrine disorder which involves multiple 
organ  systems  and  leads  to  significant  morbidity  and  mortality  due  to 
accompanying complications.
Diabetes  mellitus  has  been  defined  as  "A  metabolic  syndrome 
characterised by chronic hyperglycaemia and disturbance of carbohydrate, fat 
and protein metabolism associated with absolute or relative deficiency in insulin 
secretion and or insulin action". 
Much has been accomplished in the field  of diabetes but what has been 
troubling  one  and  all  are  the  large  macrovascular  and  micro  vascular 
complications of diabetes involving kidneys,  eyes,  blood vessels,  nerves and 
heart.Thyroid  diseases  are  also  a  common endocrinopathy  seen  in  the  adult 
population. Thyroid hormones are intimately involved in cellular metabolism.
       Thus excess or deficit of either insulin or thyroid hormones could result in 
the functional derangement of the cellular metabolism. 
  The  present  work  is  a  modest  attempt  to  study  the  prevalence  of  thyroid 
disorders in patients with  type 2 diabetes mellitus.
AIM  OF THE STUDY
1. To study the prevalence of thyroid disorders in patients with type 2 
diabetes mellitus.
2. To study the distribution of thyroid disorders in patients with  type 2 
diabetes  mellitus  regarding  age,  sex,  duration  of  diabetes,  type of 
treatment,  family  history of  diabetes  mellitus,  comorbid conditions, 
BMI and serum lipid profile.
3. To evaluate the relationship between glycemic control and occurrence 
of altered thyroid function in  type 2 diabetes mellitus.
                                  REVIEW OF LITERATURE
      Diabetes  mellitus  is  characterised  by  chronic 
hyperglycemia  with  disturbances  of  carbohydrate,  fat,  and 
protein  metabolism  resulting  from  defects  in  insulin  secretion, 
insulin action, or both.1  The metabolic dysregulation associated with 
DM  causes  secondary  pathophysiologic  changes  in  multiple  organ 
systems  that  impose  a  tremendous  burden  on  the  individual  with 
diabetes and on the health care  system. 2                                                            
PROBLEM STATEMENT
       In the first edition of the IDF Diabetes Atlas, released in 2000, the 
estimated  global  diabetes  prevalence  was  151  million.  Now  the 
estimated  diabetes  prevalence  for  2010  has  risen  to  285  million, 
representing 6.4% of the world’s adult population,  with a prediction that 
by  2030  the  number  of  people  with  diabetes  will  have  risen  to  438 
million. Far from being a disease of higher income nations, diabetes is 
very  much  a  disease  associated  with  poverty  and  disproportionately 
affecting the lower socio-economic groups. 3   Previously a disease of the 
middle aged and elderly, type 2 diabetes has recently escalated in all 
age groups and is now being seen in younger age groups.4
       Unfavourable  modification  of  lifestyle  and  dietary  habits  with 
urbanisation  are  the  most  important  factors  for  the  development  of 
diabetes. The percentage of diabetic cases  in urban areas is projected 
to increase from 54% in 1995 to 73% by the year 2025.5 According to 
IDF(2009),India  has  the  highest  number  of   people  suffering  from 
diabetes mellitus with 50.8 million and spends 2.8 billionUS$ or 1% of 
the global health expenditure for  diabetes and related problems. 6
        United Nations in 2006 in Resolution 61/225 stated that “diabetes is 
a  chronic,  debilitating  and  costly  disease  associated  with  severe 
complications, which poses severe risks for families, Member States and 
the entire world”.7
  HISTORY   
Diabetes is as old as medicine. Early evidence of description of symptoms 
of diabetes recorded in the Ebers papyrus, 1550 B.C.8  Arateus (30-90 AD), 
coined  the  term  diabetes,  meaning  “siphon,”  to  explain  the 
“liquefaction  of  the  flesh  and  bones  into  urine”.  In Greek this word 
means 'to run through' that describes 'unquenchable thirst' seen in association 
with this disease.9  Shushruta (Circa 600AD) noted this disease in Ayurveda and 
described it as "Madhumeha".10
.      In  1869,   Paul  Langerhans,  published  in  his  dissertation  on 
pancreatic histology described “clumps of  cells,” which were named 
the  islets  of  Langerhans shortly  after  his  death.11 ,12 In  1889, 
Minkowski and Von Mering, in Strassburg, Germany, discovered the 
central  role  of  the  pancreas  in  diabetes.13   In  1910,  Jean  de  Meyer 
suggested that the pancreatic secretion lacking in diabetic state to be called as 
“Insulin”  to  denote  it’s  origin  from  insulae  of  Langerhans.14  Banting  and 
Charles Best in 1921,  extracted insulin from dog's pancreas.15 
        The first chemical application of insulin was on 14 year old Leon and 
Thompson, a patient of diabetic ketoacidosis in January 1922 in Canada. This 
discovery  revolutionized  the  management  of  diabetes.  Oral  hypoglycaemic 
drugs were introduced by Frank and Fuchs in 1955.8         
               DESCRIPTION OF DIABETES MELLITUS
       When  fully  expressed,  diabetes  is  characterized  by  fasting 
hyperglycemia,  but  the  disease  can  also  be  recognized  during  less 
overt  stages,  most  usually  by  the  presence  of  glucose  intolerance. 
Diabetes  may  present  with  characteristic  symptoms  such  as  thirst, 
polyuria,blurrin of vision,weight loss and polyphagia.Hyperglycemia 
sufficient  to cause pathologic functional  changes may quite often be 
present for a long time before the diagnosis is made.1
      Patients  may  revert  to  having  impaired  glucose  regulation  or 
even normal glycemia,  particularly in recent-onset  type 2 diabetes.16 
In  type  1  diabetes,  after  a  short  period  of  insulin  treatment,  there 
may  be  a  variable  period  when  insulin  is  no  longer  required  for 
survival  and  glucose  tolerance  may  improve,  the  so-called 
honeymoon  period.  Eventually  such  patients  do  need  insulin 
treatment for survival.17
Etiologic Classification of diabetes mellitus2  
I. Type 1 diabetes  
    A. Immune mediated 
    B. Idiopathic 
II. Type 2 diabetes 
III. Other specific types 
 A. Genetic defects of ß-cell function 
 B. Genetic defects in insulin action 
C. Diseases of the exocrine pancreas 
D. Endocrinopathies 
E. Drug- or chemical induced 
F. Infections 
G. Uncommon forms of immune-mediated diabetes 
 H. Other genetic syndromes sometimes associated with diabetes 
IV. Gestational diabetes mellitus (GDM)
      
       The  majority  of  cases  of  diabetes  fall  into  two  broad 
etiopathogenetic categories, now called type 1 and type 2 diabetes.
TYPE 1 DIABETES MELLITUS 
      Type 1 diabetes is the form of the disease due primarily to β-cell 
destruction  in  which  insulin  is  required  for  survival. It  is 
characterized  by  the  presence  of  anti-GAD,  anti-islet  cell,  or  anti-
insulin  antibodies,  which  reflects  the  autoimmune  processes  that 
have led to β-cell destruction.18 ,19  
TYPE 2 DIABETES MELLITUS 
      Type  2  diabetes  is  the  most  common  form of  diabetes.  Insulin 
resistance and abnormal insulin secretion are central to the development of type 
2 DM.2 Patients  with  type  2  diabetes  usually  have  insulin  resistance 
and  relative,  rather  than  absolute,  insulin  deficiency  and  are 
associated with progressive β-cell failure with increasing duration of 
diabetes.20  The  risk  of  developing  type  2  diabetes  increases  with 
age, obesity, physical inactivity and family history of diabetes. 1 The 
disease  can  occur  at  any  age  and  is  now  seen  in  children  and 
adolescents.21 
Diagnostic criteria for diabetes mellitus22 
Symptoms of diabetes plus random plasma glucose concentration  ≥ 200 mg/dl 
(11.1 mmol/l). Random is defined as any time of day without regard to time 
since last meal. The classic symptoms of diabetes include polyuria, polydipsia 
and unexplained weight loss                                                  (or)                         
 FPG ≥ 126 mg/dl (7.0 mmol/l). Fasting is defined as no caloric intake for at 
least 8 hours.                                                                        (or)
2 hours post load glucose ≥ 200 mg/dl (11.1 mmol/l) during an OGTT. The test 
should be performed as described by WHO, using a glucose load containing the 
equivalent of 75 gm anhydrous glucose dissolved in water. 
        In the absence of unequivocal hyperglycaemia these criteria should be 
confirmed by repeat testing on a different day. FPG is the most reliable and 
convenient test for identifying DM in asymptomatic individuals. HbA1C is not 
currently recommended to diagnosis of diabetes.
IMPAIRED GLUCOSE TOLERANCE1
      Defined  as  2 hours values in the oral glucose tolerance test (OGTT) 
between 140 and 199mg/dl (7.8 and 11.1 mmol/L).   Glucose  tolerance  is 
above  the  conventional  normal  range  but  lower  than  the  level 
diagnostic  of  diabetes.  Persons  with  IGT   have  a  high  risk  of 
developing  diabetes  and  arterial  disease. IGT  is  more  frequent  in 
obese   persons  and  often  is  associated  with  hyperinsulinemia  and 
insulin resistance.
IMPAIRED FASTING GLUCOSE1
      Defined as  fasting plasma glucose concentrations of 100 to 125 
mg/dL (5.6 to <7.0 mmol/L). IFG is also a stage of impaired glucose 
homeostasis  with  fasting  glucose  levels  were  above  normal  but 
below those diagnostic for diabetes.
ACUTE COMPLICATIONS OF DM2
        Diabetic ketoacidosis (DKA) and hyperglycemic hyperosmolar state 
(HHS) are acute complications of diabetes. DKA primarily occurs in type 
1  DM but,  can  also  occur  in  type  2  DM.   HHS is  primarily  seen  in 
individuals with type 2 DM. Both disorders are associated with absolute 
or  relative  insulin  deficiency,  volume  depletion,  and  acid-base 
abnormalities. 
CHRONIC COMPLICATIONS OF DM2
       The  vascular  complications  of  DM  are  divided  into  microvascular 
(retinopathy,  neuropathy,  nephropathy)  and  macrovascular  complications 
[coronary  artery  disease  (CAD),  peripheral  arterial  disease  (PAD), 
cerebrovascular disease]. Nonvascular complications include problems such as 
gastroparesis, infections, and skin changes.  
        The microvascular complications of both type 1 and type 2 DM 
result from chronic hyperglycemia. Evidence implicating a causative role 
for  chronic  hyperglycemia  in  the  development  of  macrovascular 
complications   were  inconclusive.  Other  factors  (dyslipidemia  and 
hypertension) also play important roles in macrovascular complications. 
DYSLIPIDEMIA IN DIABETES
      The dyslipidemia in type 2 diabetes and insulin resistance 
typically  consists  of  elevated triglycerides and decreased HDL 
cholesterol  level23 and  of  qualitative  abnormality  in  the  LDL 
structure, i.e., decreased size and increased density of the LDL 
particle.24 
METABOLIC SYNDROME AND OBESITY25
        The  metabolic  syndrome  (syndrome  X,  insulin  resistance 
syndrome)  consists  of  a  constellation  of  metabolic  abnormalities  that 
confer  increased  risk  of  cardiovascular  disease  (CVD)  and  diabetes 
mellitus (DM).   Diagnosis  of  the  metabolic  syndrome  requires 
the presence of at least three of the following five criteria:26 
1. elevated fasting plasma glucose levels (>110 mg/dL), 
2. visceral  obesity  (waist  circumference  >35  inches  in 
women and 40 inches in men),
3. hypertension (>130/85 mm Hg), 
4. hypertriglyceridemia (>150 mg/dL) and
5. low high-density lipoprotein (HDL) cholesterol (<40 mg/dL 
in men and <50 mg/dL in women)
                                    THYROID  
The thyroid (Greek thyreos, shield, plus eidos, form) consists of two lobes 
that are connected by an isthmus. It is located anterior to the trachea between 
the cricoid cartilage and the suprasternal notch. Four parathyroid glands, which 
produce parathyroid hormone are located posterior to each pole of the thyroid.27 
        The normal  thyroid gland secretes sufficient  amounts of the thyroid 
hormones  triiodothyronine  (T3) and  tetraiodothyronine  (T4,  thyroxine)  to 
normalize  growth  and  development,  body  temperature,  and  energy  levels. 
Calcitonin, the second type of thyroid hormone, is important in the regulation of 
calcium metabolism.28 
BIOSYNTHESIS OF THYROID HORMONES27 
         Iodide, ingested from food, water, or medication, is rapidly absorbed from 
intestine and enters an extracellular  fluid pool.   Transport of iodide into the 
thyroid gland  is by an intrinsic follicle cell basement membrane sodium/iodide 
symporter  (NIS).  At  the apical  cell  membrane a  second I- transport  enzyme 
called pendrin  is present.  Iodide is oxidized by thyroidal peroxidase to iodine 
that  rapidly  iodinates  tyrosine  residues  within  the  thyroglobulin  molecule  to 
form monoiodotyrosine (MIT) and diiodotyrosine (DIT). This process is called 
iodide organification.Two molecules of DIT combine within the thyroglobulin 
molecule to form       L-thyroxine (T4). One molecule of MIT and one molecule 
of  DIT  combine  to  form  T3.  T4,  T3,  MIT,  and  DIT  are  released  from 
thyroglobulin  by  exocytosis  and  proteolysis  of  thyroglobulin  at  the  apical 
colloid  border.  Most  of  the  hormone  released  is  thyroxine.  Most  of  the  T3 
circulating in the blood is derived from peripheral metabolism of T4. 
       Both hormones are bound to plasma proteins, including thyroxine 
binding globulin (TBG); transthyretin (TTR); and albumin.  The plasma 
binding  proteins  increase  the  pool  of  circulating  hormone,  delay 
hormone clearance,  and may modulate  hormone delivery to  selected 
tissue sites. 
DEIODINASES27
     T4 is converted to T3 by the deiodinase enzyme.
1.  Type I deiodinase, which is located primarily in thyroid, liver, and 
kidney, has a relatively low affinity for T4.
2. Type  II  deiodinase  has  a  higher  affinity  for  T4 and   is  found 
primarily in the pituitary gland, brain, brown fat, and thyroid gland.
3. Type  III  deiodinase  inactivates  T4 and  T3 and  is  the  most 
important source of reverse T3 (r T3)
PHYSIOLOGICAL EFFECTS OF THYROID HORMONES29
  Heart                 : Increases  number of β adrenergic receptors
                             Enhances response to catecholamines  
Adipose tissue      : Stimulate lipolysis
Muscle                 : Increases protein breakdown
Bone                    : Promote growth and development
Nervous system    : Promote normal brain development
Gut                      : Increases carbohydrate absorption
Lipoprotein           : Stimulate LDL receptors
Others                  :  Increases metabolic rate and oxygen consumption            
REGULATION OF THYROID AXIS27
The thyroid axis is a classic example of an endocrine feedback loop. 
TRH stimulates pituitary production of  TSH, which,  in turn, stimulates 
thyroid hormone synthesis and secretion. Thyroid hormones feed back 
to inhibit TRH and TSH production .  
EXOGENOUS  AND  ENDOGENOUS  FACTORS  SUPPRESSING 
TSH SECRETION:30       
        Dopamine  and  agonists,  Somatostatin,  Dobutamine, 
Glucocorticoids, Interleukins, TNF-α, Thyroid hormones and Phenytoin. 
FACTORS ASSOCIATED WITH ALTERED BINDING OF THYROXINE 
BY THYROXINE-BINDING GLOBULIN30
Increased Binding:
       Pregnancy, Oral contraceptives, Infectious hepatitis, Cirrhosis, HIV, 
Acute intermittent porphyria and Tamoxifen.
Decreased Binding 
       Androgens, Large doses of glucocorticoids, acromegaly, Nephrotic 
syndrome , Major systemic illness and Psychiatric illness.
FACTORS ASSOCIATED WITH DECREASED CONVERSION OF T4 
TO T3:30
        Fetal life, Caloric restriction, Hepatic disease, Major Systemic illness, 
Propylthiouracil, Glucocorticoids, Propranolol, Iodinated X-ray contrast agents, 
Amiodarone and Selenium deficiency. 
HYPOTHYROIDISM
       Hypothyroidism is the condition resulting from a lack of effects of thyroid 
hormones on body tissues.31
Symptoms
    Tiredness,  weaknes, Dry  skin  ,Feeling  cold,Hair  loss, Difficulty 
concentrating  and  poor  memory,  Constipation,  Weight  gain  with  poor 
appetite,Dyspnea,Hoarse  voice,   Menorrhagia  (later  oligomenorrhea  or 
amenorrhea), Paresthesia  and Impaired hearing.
Signs
        Dry coarse skin; cool peripheral extremity,   Puffy face, hands, and feet 
(myxedema), Diffuse alopecia, Bradycardia,  Peripheral edema, Delayed tendon 
reflex relaxation,  Carpal tunnel syndrome and  Serous cavity effusions27
METABOLIC  ABNORMALITIES IN HYPOTHYROIDISM
       Hypothyroidism is  associated with a reduction in glucose disposal  to 
skeletal  muscle  and  adipose  tissue  and  also  associated  with  reduced 
gluconeogenesis. The net effect of these influences is usually minimal on serum 
glucose  levels.  Degradation  of  insulin,  is  slowed  and  the  sensitivity  to 
exogenous insulin may be increased.32 Both the synthesis and the degradation of 
lipid are depressed in hypothyroidism with a net effect of accumulation of LDL 
and  triglycerides.  HDL concentrations  and  Plasma  free  fatty  acid  levels  are 
decreased.33.  
SUBCLINICAL HYPOTHYROIDISM
       Defined as a low-normal free T4 but a slightly elevated serum TSH 
level.   The  TSH  elevation  in  such  patients  is  modest,  with  values 
typically  between  4  and  15  mU/L.33 Rates  of  progression  to  overt 
hypothyroidism  ranges  from  3% to 8% per year,  higher rates seen in 
individuals  with  initial  TSH concentration  greater  than  10   mU/L  and 
those  with  positive  anti-TPO  antibodies.34 The  association  of  mild 
hypothyroidism with an increase in risk for atherosclerotic heart disease 
has been shown by some,  but not others.35,36   . 
HYPERTHYROIDISM27
       Hyperthyroidism is a state when thyrotoxicosis occurs because of sustained 
over production of hormones by thyroid gland.
Symptoms
      Heat intolerance and sweating, Palpitation,  Fatigue and weakness, Weight 
loss with increased appetite, Diarrhea,  Polyuria,  Oligomenorrhea, and  loss of 
libido.
Signs
       Tachycardia; atrial fibrillation in the elderly, Tremor, Goiter, Warm, moist 
skin,Muscle  weakness,  proximal  myopathy,  Lid  retraction  or  lag  and 
Gynecomastia.
METABOLIC ABNORMALITIES IN HYPERTHYROIDISM
       Preexisting  diabetes  mellitus  may  be  aggravated,  one  cause  being 
accelerated turnover of insulin.37 Both lipogenesis and lipolysis are increased in 
thyrotoxicosis, but the net effect is lipolysis, as reflected by an increase in the 
plasma concentration of free fatty acids and glycerol and a decrease in serum 
cholesterol level.Triglyceride levels are usually slightly decreased.38
SUBCLINICAL HYPERTHYROIDISM
        There are no  signs of thyrotoxicosis but the serum TSH is subnormal 
despite normal serum free T4 concentration.37 Subclinical hyperthyroidism may 
accelerate bone loss in postmenopausal women39 and increases the incidence of 
atrial arrhythmias including atrial fibrillation in elderly patients.31 
 
                 
                DIABETES AND THYROID DISEASES
       Diabetes  mellitus  and  thyroid  diseases  are  the  two  common 
endocrinopathies seen in the adult population. Insulin and thyroid hormones are 
intimately involved in cellular metabolism.  Excess or deficit of either of these 
hormones could result in the functional derangement of the other.40
EFFECT OF DIABETES ON THYROID FUNCTION
       In euthyroid individuals with diabetes mellitus, the serum T3 levels, basal 
TSH levels and TSH response to thyrotropin releasing hormone (TRH) may all 
be strongly influenced by the glycemic status.41  Poorly controlled diabetes, both 
Type 1 and Type 2, may induce a “Low T3 state” characterized by low serum 
total and free T3 levels, increase in reverse T3 (r T3) but near normal serum T4 
and  TSH  concentrations.42  Low  serum  T3 is  due  to  reduced  peripheral 
conversion of thyroxine (T4) to tri-iodothyronine (T3) via 5’ monodeiodination 
reaction and may normalize with improvement in glycemic status but even with 
good diabetes control, the normal nocturnal TSH peak may not be restored in 
C-peptide negative patients.43
  EFFECT OF DIABETES MELLITUS ON THYROID DISEASES 
Dysthyroid  optic  neuropathy  (DON)  resulting  in  blindness  is  the  most 
threatening  complication  of  Graves’  orbitopathy  (GO).  It  is  due  to  the 
compression of optic nerve by enlarged extraocular muscles at the orbital apex. 
Incidence of DON in patients with diabetes mellitus is higher than that seen in 
control “GO” group and the recovery after treatment is also poor. This has been 
explained by reduced oxygenation of optic nerve in diabetic patient owing to the 
vasculopathy making it more susceptible to the pressure effect.44
EFFECT OF HYPERTHYROIDISM ON GLYCEMIC STATUS
Graves disease is the commonest cause of hyperthyroidism. While Graves 
disease may be associated with type 1 diabetes in polyglandular autoimmune 
syndrome,  thyrotoxicosis  by  itself  is  diabetogenic.  Frank  diabetes  occurs  in 
2-3%, when hyperthyroidism develops in normal individuals. In known diabetic 
patients   hyperthyroidism  causes  deterioration  of  glycemic  control  status.42 
These changes are due to alteration in following systems:-
1. Gastrointestinal System
In  hyperthyroidism,  there  is  accelerated  gastric  emptying,  enhanced 
intestinal glucose absorption and an increase in portal venous blood flow.44
2. Insulin Secretion
        Insulin secretion decreases in hyperthyroidism.45,46  Insulin clearance rate is 
reported to be increased by about 40%.47 Long term thyrotoxicosis has been 
shown  to  cause  beta  cell  dysfunction  resulting  in  poor  insulin  response  to 
glucose.48
3. Endogenous Glucose Production
       In hyperthyroidism the endogenous glucose production is greatly increased 
by  a  variety  of  mechanisms:  (a)  there  is  an  increase  in  the  availability  of 
gluconeogenic  precursors(  lactate,  glutamine,  alanine  and  FFA)  stimulating 
hepatic  gluconeogenesis;49 (b)  Inhibition  of  glycogen  synthesis;50 
(c)  Upregulation  of  GLUT-2  glucose  transporters  protein  expression  in  the 
hepatocyte;51 (d) Increased secretion and exaggerated effects of glucagon and 
adrenaline on liver cells.49    
4. Glucose utilization 
In adipocytes isolated from rats, the sensitivity of glucose transport and 
utilization to insulin has been found to be normal, increased or decreased.45   In 
skeletal muscle, there is a preferential increase in glucose uptake and lactate 
formation  .  This  is  due  to  increase  in  GLUT-1  and  GLUT-4  transporters52, 
increased   glycogenolysis  due  to  beta  adrenergic  stimulation49 ,increased 
activity of hexokinase and 5 phosphofructokinase.53
Thus  the  net  effect  of  changes  occurring  at  various  levels  such  as 
gastrointestinal tract, beta cells, hepatocytes, adipocytes and skeletal muscles is 
hyperglycemia.
EFFECT OF HYPOTHYROIDISM ON GLYCEMIC STATUS
In hypothyroidism, the synthesis and release of insulin is decreased.46 The 
rate  of  hepatic  glucose  output  is  decreased  probably  due  to  reduced 
gluconeogenesis.  A  post  receptor  defect  has  been  proposed  to  explain  the 
decrease in insulin stimulated glucose utilization in peripheral tissues.49 The net 
effect is an increased risk of recurrent hypoglycemia in a diabetic individual.54
ASSOCIATION BETWEEN DIABETES MELLITUS AND   THYROID 
DISORDERS: 
        Celani MF et al  in their study  found that abnormal TSH values in type 2 
diabetic patients found before tight glycemic control  reverted to normal values 
with adequate treatment of diabetes with OHA or insulin. They suggested that 
the diagnosis of thyroid dysfunction in type 2 diabetes should be delayed until 
improvement of metabolic status.55   
        Proces S et al  in their study found that in diabetic patients TSH was lower 
than in non diabetic subjects. They concluded that besides known parameters 
such as age and drugs, thyroid function tests can also be altered in diabetes 
mellitus and obesity.56  
       Warren RE et al  in their study found that serum thyrotropin (i.e. baseline 
TSH) is a better predictor of thyroid dysfunction than thyroid autoantibodies in 
people with diabetes.57 
        Vondra K et al  in their study  found that prevalence of thyroid disease in 
diabetic patients is 2-3 times higher than in non diabetic subjects. It raises with 
age and is strongly influenced by female gender and autoimmune diabetes. They 
even  recommended  thyroid  disease  screening and diagnosis  in  patients  with 
diabetes mellitus.58          
        Abdel Rahman et al  in their study found that  overall prevalence of thyroid 
diseases was 12.5% in  type 2 diabetes mellitus group. The study suggested that 
diabetic patients should be screened for asymptomatic thyroid dysfunction.59
            Perros P et al in their study  found that the prevalence of thyroid disease 
was  13.4%  in  a  randomly  selected  group  of  1310  adult  diabetic  patients 
attending  a  diabetic  clinic.  They  suggested  that  thyroid  function  should  be 
screened  annually  in  diabetic  patients  to  detect  asymptomatic  thyroid 
dysfunction which is increased in frequency in a diabetic population.60  
        Smithson MJ  in his study  found that the prevalence of thyroid disease 
(previously  known  and  diagnosed  as  a  result  of  screening)  in  the  entire 
population of diabetic patients in his sample of 4300 general practice patients 
was  10.8%.  He  concluded  by  suggesting  that  screening  for  thyroid  disease 
should be considered in patients receiving diabetes care in community.61 
         Zdrojewicz Z et al in their study  found that there was no difference in 
thyroid  gland  function  in  patients  with  non  insulin  dependent  diabetes 
mellitus(type  2)  and  different  therapies  have  no  influence  on  thyroid  gland 
function.62  
       Parr JH et al  in their study found that improvement in long term metabolic 
control  did not  influence free thyroid hormone levels  in well  controlled and 
moderately-poor controlled diabetics taking insulin.63  
        Chubb SA et al in their study found that none of those patients  with type 2 
diabetes  diagnosed  of  subclinical  hypothyroidism  has  overt  hypothyroidism 
when restudied after 5 years. So they concluded that subclinical hypothyroidism 
is a common but incidental finding and routine screening of thyroid function in 
type 2 diabetes is questionable.64
                                       MATERIALS  AND  METHODS
        The present study titled "Thyroid Profile in Type 2  Diabetes Mellitus" 
was  carried  out  in  the  Department  of  Medicine  and  in  the  Department  of 
Diabetology, kilpauk medical college and hospital (Chennai).
1. Study design     :  Cross sectional study.
2. Period of study:  January 2009 to October 2009
3. Materials       :  Questionnaire, BMI calculation, Blood pressure, FBS, 
PPBS,  Blood  Urea,   Serum  creatinine,,   Urinalysis,  urine  spotPCR 
(Protein  Creatinine  Ratio),ECG,  Chest  X  ray,  Fasting  lipid  profile, 
Thyroid profile(FT3, FT4  and TSH),  HbA1C, Fundus examination. 
4. Study group    :    The study group    included   108  persons with known 
type 2 diabetes mellitus or newly  detected  Type 2 diabetes mellitus with 
out known thyroid disorders  either admitted in wards or attending the 
outpatient departments who met the inclusion criteria. 
Inclusion criteria 
        Known type 2 diabetes mellitus and Newly detected type 2 diabetes mellitus 
subjects who gave informed consent to participate in the study.
Exclusion criteria
• Patients not willing for study
• Patients with known thyroid disease
• Patients with chronic renal failure and Diabetic nephropathy.
• Patients with acute illness( sepsis, acute MI, severe heart failure, recent 
admission in intensive care unit)
• Patients with hepatic dysfunction
• Patients  with psychiatric illness.
• Pregnancy
• Patients  on  treatment with  drugs  interfering  with thyroid function 
(amiodarone, propranolol, corticosteroids  and  oral contraceptives)      
        All patients in the study group were selected without any bias for sex, 
duration, severity or control of diabetes. A thorough history was recorded with 
particular emphasis on symptoms of hypothyroidism and hyperthyroidism. The 
presence of  associated illness  like coronary artery  disease,  hypertension  and 
cerebrovascular  accident   were  noted.  Family  history  regarding  diabetes 
mellitus  and treatment  history  of  oral  hypoglycaemics  or  insulin  along with 
duration was also included. 
        A thorough general and systemic examination was carried. The fundus 
examination for diagnosis of diabetic retinopathy and neurological examination 
for diabetic neuropathy were also done. 
BMI calculation
        Body mass index (BMI) is calculated with height and weight of the subject 
using the following   formula.
BMI= weight (kg) / height (m)2 
Blood sugar
        Both fasting and postprandial blood sugar are estimated by Trinder’s 
(Glucose oxidase) method and read at 505/670 nm. 
Renal function test
        The Blood Urea in this study was estimated using DAM method (Diacetyl 
Monoxime). Serum creatinine was estimated using Modified Jaffe’s method. 
Urinalysis
        Urine sample is collected for urine routine analysis which includes sugar, 
protein, cytology and urinary sediments 
Urine spot PCR
        Urine sample is  collected to  estimate  protein creatinine ratio.  Sulfo 
salicylic precipitation method used for protein estimation.
Lipid Profile
        Total cholesterol,Triglyceride (TGL), Low Density Lipoprotein (LDL) and 
High Density Lipoprotein (HDL) levels were analysed  in the early morning 
fasting Blood Sample.
Methods used: 
1. Total cholesterol- CHOD POD METHOD
2. HDLC                  -Selective immune precipitation method
3. Triglycerides      - Enzymatic calorimetric method
4. LDLC                   - Derived from  TC  and TGL values.                           
5. VLDL                  - Derived from triglyceride values
HbA1C
        Blood sample collected in EDTA coated tubes and HbA1C is estimated by 
Biorad- HPLC method.
Thyroid Profile
        Estimation done in fasting serum sample.
   Methods used: 
    1.TSH  - Ultrasensitive sandwich chemi luminescent immuno assay
    2. FT3  & FT4   -  Competitive chemi luminescent immuno assay.
DEFINITIONS
Diabetes Mellitus
        The WHO in consultation with an expert committee of the American 
Diabetes Association has approved the following diagnostic criteria for 
Diabetes Mellitus,which was used to diagnose new cases.
       The patients on antidiabetic therapy were also considered as having 
diabetes mellitus.
                                    
Fasting: No caloric intake for atleast 8 hours.
2-3 days of unrestricted carbohydrated diet prior to the test.
No physical activities during the procedures.
Systemic Hypertension (As per the JNC VII Guidelines)
        Subjects on medications for hypertension and those who had a systolic 
blood pressure of ≥ 140 mmHg and / or diastolic blood pressure  ≥ 90 mmHg 
were considered to have hypertension.
Dyslipidemia
        Adult Treatment Panel III (ATP III) guidelines developed by the National 
Cholesterol Education Program have been used to detect dyslipidemia in the 
study  subjects.  Diabetes  mellitus  is  considered  as  Coronary  Heart  Disease 
equivalent.   According to the guidelines: 
Overweight and Obesity
        BMI (WHO criteria for Asian population)  is used for classifying the 
subjects according to the weight status.
BMI Group BMI(kg/m2)
Underweight < 18.5
Normal weight 18.5-22.9
Overweight    23-29.9
Obesity ≥ 30.0
Thyroid  profile
Reference values:   FT3      : 1.7-4.2  pg/ml      TSH :  0.35-5µIU/ml    
                                 FT4     : 0.7- 1.8 ng/dl 
• Overt  hypothyroidism is defined as TSH >5.5 µIU/ml with FT4 < 0.7 ng/
dl. 
• Subclinical hypothyroidism is defined as TSH > 5µIU/ml with normal 
FT3  and FT4 levels 
• Overt hyperthyroidism is defined as TSH  < 0.3  µIU/ml with FT4  > 1.8 
ng/dl 
• Subclinical hyperthyroidism is defined as TSH < 0.3 µIU/ml with normal 
FT3 and FT4 levels 
                                      RESULTS AND ANALYSIS
       The present study titled “Thyroid Profile in Type 2 Diabetes Mellitus” 
was undertaken in the Department of Medicine and Department of Diabetology, 
kilpauk medical college and hospital(Chennai) over a period of 10 months from 
January  2009 to october 2009 .
        The study sample included   108 type 2 diabetes patients in the wards and 
outpatient departments. Following were the observations:
                          
                            Age Distribution of Cases
                                             Table-1
Age Group (yrs) No. of cases Percentage
Upto 40 14 13.0
41-60 78 72.2
61 or more 16 14.8
Total 108 100.0
                  Distribution of Cases According to Sex
                                             Table-2
Gender No. of cases Percentage
Male 44 40.7
Female 64 59.3
Total 108 100.0
                     . 
       Distribution According to Duration of Diabetes Mellitus
                                             Table-3
Duration of DM
(in years)
No. of cases Percentage
Up to 5 years 76 70.4
6-10 years 20 18.5
>10 years 12 11.1
Total 108 100.0
                
           Distribution according to Type of treatment
                                             Table-4                 
              
          Distribution According to Regularity of treatment
                                             Table-5
Regularity of treatment No. of cases Percentage
Regular 82 75.9
Irregular 20 18.5
Newly detected Diabetic patients 6 5.6
Total 108 100.0
     Distribution according to Family history of Diabetes Mellitus
                                             Table-6
Family h/o DM No. of cases Percentage
Yes 42 38.9
No 66 61.1
Total 108 100.0
         Distribution  of cases according to  Systemic Hypertension
                                             Table-7
Systemic Hypertension No. of cases Percentage
Yes 54 50.0
No 54 50.0
Total 108 100.0
       Distribution of cases according to Coronary Artery Disease
                                             Table-8
CAD No.  of cases Percentage
Yes 12 11.1
No 96 88.9
Total 108 100.0
               
              
           Distribution of cases according to Retinopathy
                                             Table-9
                      
                                  
      
                Distribution of cases according to BMI
                                         Table-10
BMI Group (Kg/m2) No. of cases Percentage
< 18.5 2 1.9
18.5-22.9 42 38.9
   23-29.9 48 44.4
≥ 30 16 14.8
Total 108 100.0
        Among the study population, 59.2%(64/108)  were overweight and obese; 
38.9%(42/108) had normal BMI.                                       
           Distribution of cases according to HbA1C level
                                         Table-11
HbA1C level No. of cases Percentage
≤ 6 2 1.9
6.1 - 8 50 46.3
> 8 56 51.9
Total 108 100
                 
         Among the study group, 56(51.9%) patients had HbA1C level more than 
8% and 52(48.2%) patients had 8 or less. 
          
       Distribution of cases according to Altered lipid profile
                                         Table-12
Altered lipid profile No. of cases Percentage
TC 54 50%
LDL-C 78 84.24%
HDL-C 40 43.2%
TGL 54 50%
                       
        The above table shows that  50% (54/108) of the study group had raised 
total  cholesterol  level.  84.24%(78/108)   had  raised  LDL-C  level;  43.2% 
(40/108)  had  decreased  HDL-C  level  and  50%  (54/108)  had 
hypertriglyceridemia.
     Distribution of Cases according to Abnormal thyroid profile 
                                             Table-13
Thyroid Function No. Percentage
With normal thyroid profile 94 87.0
With abnormal thyroid profile 14 13.0
Total 108 100.0
       The above table shows 13% (14/108) of the patients with diabetes mellitus 
in the study group had abnormal thyroid profile.
                      Distribution of thyroid diseases
                                            Table-14 
Thyroid profile No.of cases Percentage
Normal 94 87
Overt hypothyroidism 0 0
Subclinical hypothyroidism 12 11.1
Overt hyperthyroidism 0 0
Subclinical hyperthyroidism 2 1.9
Total 108 100
        
        The above table shows that  11.1% (12/108) of the patients had report 
suggestive of sub clinical hypothyroidism and 1.9% (2/108) of the patients had 
report suggestive of sub clinical hyperthyroidism. 
                                            
               
                     Abnormal thyroid profile Vs Age group
                                            Table-15
Abnormal thyroid profile
Age 
group(yrs) No Yes Total
Up to 40 count 12 2 14
% within abnormal 
thyroid profile
12.8% 14.3% 13.0%
% of total 11.1% 1.9% 13.0%
41 - 60 count 68 10 78
% within abnormal 
thyroid profile
72.3% 71.4% 72.2%
% of total 63.0% 9.3% 72.2%
>60 count 14 2 16
% within abnormal 
thyroid profile
14.9% 14.3% 14.8%
% of total 13.0% 1.9% 14.8%
Total count 94 14 108
% within  abnormal 
thyroid profile
100.0% 100.0% 100.0%
% of total 87.0% 13.0% 100.0%
P  = 0.987                                                                                       Not significant
        Out of 14 patients with abnormal thyroid profile, 2 patients(14.3%) were 
found to be of age 61years and more,  10 (71.4%) were found to be of age 
between  41-60  years  and   2(14.3%)   were  found  to  be  40  years  or  less. 
Compared  with normal thyroid profile group it has no statistical significance.
                    Abnormal thyroid profile Vs Sex
                                            Table-16
Sex Abnormal thyroid profile
No Yes Total
Male count 42 2 44
%within abnormal 
thyroid profile
44.7% 14.3% 40.7%
% of total 38.9% 1.9% 40.7%
Female count 52 12 64
%within abnormal 
thyroid profile
55.3% 85.7% 59.3%
% of total 48.1% 11.1% 59.3%
Total count 94 14 108
%within abnormal 
thyroid profile
100.0% 100.0% 100.0%
% of total 87.0% 13.0% 100.0%
    
    P   = 0.031                                                                                        Significant
        Out of 14 patients with abnormal thyroid profile, 14.3%(2) were males and 
85.7%(12) were females. Compared  with normal thyroid profile  group, this is 
statistically significant .                                         
          
                Abnormal thyroid profile Vs Duration of Diabetes
                                             Table-17
Duration
(yrs) Altered thyroid profile
No Yes Total
Up to 5 Count 70 6 76
% within abnormal 
thyroid profile
74.5% 42.9% 70.4%
% of total 64.8% 5.6% 70.4%
6 -10 Count 16 4 20
%within abnormal 
thyroid profile
17.0% 28.6% 18.5%
% of total 14.8% 3.7% 18.5%
>10 Count 8 4 12
%within abnormal 
thyroid profile
8.5% 28.6% 11.1%
% of total 7.4% 3.7% 11.1%
Total Count 94 14 108
%within abnormal 
thyroid profile
100.0% 100.0% 100.0%
% of total 87.0% 13.0% 100.0%
p = 0.028                                                                                              Significant 
        Among the 14 patients with abnormal thyroid profile, 28.65%(4) had 
Diabetes more than 10 years, 28.6%(4) had duration between 6-10 years and 
42.9%(6) had Diabetes 5 years or less. Compared with normal thyroid group it 
is statistically significant.
         Abnormal thyroid profile  Vs  Type of treatment 
                                         Table-18   
                                          
 P   = 0.293                                                                                    Not Significant
                                    
         Out of 14 patients with thyroid abnormality, 57.1%(8) were on OHA, 
14.3%(2) were on  Insulin and the rest (28.6%) were on  both OHA/Insulin. 
Compared with normal  thyroid group it has no statistical significance . 
       
           Abnormal thyroid profile Vs  Family history of Diabetes 
                                             Table-19
Family history of 
DM
Abnormal thyroid 
profile
No Yes Total
No Count 66 0 66
%within abnormal 
thyroid profile
70.2% .0% 61.1%
% of total 61.1% .0% 61.1%
Yes Count 28 14 42
%within abnormal 
thyroid profile
29.8% 100.0% 38.9%
% of total 25.9% 13.0% 38.9%
Total Count 94 14 108
%within abnormal 
thyroid profile
100.0% 100.0% 100.0%
% of total 87.0% 13.0% 100.0%
    P   = 0.000                                                                                        Significant
                                    
        All patients with thyroid abnormality had family history of diabetes, but 
only 29.8%(28) of normal thyroid group had it.  Statistically the difference is 
significant.  
                                         
                                              
                    
              Abnormal thyroid profile  Vs  Hypertension
                                             Table-20
    P   = 0.567                                                                                 Not Significant
       Out  of  14  patients  with  abnormal  thyroid  profile,  57.1%(8)  had 
Hypertension and the rest(42.9%) did not. Compared with patients with normal 
thyroid profile, it has no statistical significance. 
                                                      
              
             Abnormal thyroid profile Vs Coronary artery disease
                                             Table-21
CAD Abnormal thyroid profile
No Yes Total
No count 84 12 96
% within abnormal 
thyroid profile
89.4% 85.7% 88.9%
% of total 77.8% 11.1% 88.9%
Yes count 10 2 12
%within abnormal 
thyroid profile
10.6% 14.3% 11.1%
% of total 9.3% 1.9% 11.1%
Total count 94 14 108
%within abnormal 
thyroid profile
100.0% 100.0% 100.0%
% of total 87.0% 13.0% 100.0%
    
    P   = 0.685                                                                                Not Significant
        Out of 14 patients with abnormal thyroid profile, 14.3%(2) had CAD and 
rest(85.7%) had no CAD. Compared with normal thyroid profile group this is 
not statistically significant.   
               Table-22 :  Abnormal Thyroid Profile Vs  BMI
    
p = 0.158                                                                                        Not significant
  
       Out  of  14  persons  with  abnormal  thyroid  profile,  71.5%(10)  were 
overweight and obese. Compared with normal thyroid profile group this is not 
statistically significant.               
           Abnormal Thyroid Profile Vs  HbA1C Level 
                                            Table-23 
HbA1C Abnormal thyroid 
profile
( %) No Yes Total
≤ 6 count 2 0 2
% within abnormal thyroid 
profile
2.1% .0% 1.9%
% of total 1.9% .0% 1.9%
6.1 - 8 count 44 6 50
% within abnormal thyroid 
profile
46.8% 42.9% 46.3%
% of total 40.7% 5.6% 46.3%
>8 count 48 8 56
% within abnormal thyroid 
profile  
51.1% 57.1% 51.9%
% of total 44.4% 7.4% 51.9%
Total count 94 14 108
% within abnormal thyroid 
profile
100.0% 100.0% 100.0%
% of total 87.0% 13.0% 100.0%
                                                                                                                
p=0.268                                                                                  Not significant
        Out of 14 patients with altered thyroid profile, 57.1%(8) had HbA1C value 
above  8% and  the  remaining(42.9%)  had  HbA1C 8  or  less.  Compared  with 
normal thyroid profile group this is not statistically significant . 
        
            Abnormal Thyroid Profile  Vs  Total cholesterol
                                            Table-24
Abnormal thyroid 
profile No. Mean
Std. 
Deviation
Std. Error of 
Mean
Yes 14 230.49 89.852 24.014
No 94 201.7 52.098 5.374
p = 0.08                                                                                          Not significant
       The mean total cholesterol level of patients with abnormal thyroid profile 
was  230.49  mg/dl  and  for  the  normal  thyroid  group  was  201.7  mg/dl. 
Comparing the two groups, the difference is statistically insignificant.
                                            
            Abnormal  Thyroid Profile Vs  LDL cholesterol
                                            Table-25
p = 0.088                                                                                Not significant
                  The mean LDL- C  level of patients with abnormal thyroid profile 
was  137.34  mg/dl  and  that  of  normal  thyroid  group  was  118.7  mg/dl. 
Comparing the two groups the difference is statistically not significant.
        
           Abnormal  Thyroid Profile  Vs  HDL cholesterol
                                            Table-26
p = 0.155                                                                                Not significant
        The mean HDL- C  level of patients with abnormal thyroid profile was 
51.44 mg/dl and that of normal thyroid group was 46.14 mg/dl. Comparing the 
two groups the difference is statistically not significant.
                
             Abnormal  Thyroid Profile  Vs  Triglyceride 
                                             Table-27 
p = 0.524                                                                                Not significant
        The mean Triglyceride  level of patients with abnormal thyroid profile was 
211.66 mg/dl and that of normal thyroid group was 186.89 mg/dl. Comparing 
the two groups the difference is statistically not significant.
BINARY LOGISTIC REGRESSION
• Binary logistic  regression model was used to identify the risk factors 
associated with  abnormal  thyroid profile  in diabetic population. 
• The dependent variable is  Abnormal thyroid  profile.
• The independent variables tested  are   Sex,  Duration of diabetes mellitus 
and Family history of diabetes mellitus.
        The  analysis  report  showed   significant correlation between  altered 
thyroid profile and the  female gender.
                                                        DISCUSSION 
      Diabetes mellitus is the most common endocrine disorder which involves 
multiple organ systems and leads to significant morbidity and mortality due to 
accompanying  complications.  Thyroid  diseases  are  also  a  common 
endocrinopathy seen in the adult population. Thyroid hormones are intimately 
involved  in  cellular  metabolism.  Thus  excess  or  deficit  of  either  insulin  or 
thyroid  hormone  could  result  in  the  functional  derangement  of  the  cellular 
metabolism.
      In the present study patients of diabetes mellitus were taken from Medical 
and  Diabetic  Outpatient  Departments,  Male  &  Female  medical  wards  of 
kilpauk medical college and hospital(Chennai) over a period of 10 months from 
January  2009 to  october  2009  and  they  were  evaluated  for  altered  thyroid 
profile. 
AGE DISTRIBUTION
       In the present study of 108 type 2 diabetic patients, , 14 patients (13%) 
were up to 40 years, ,  78 patients (72.2%) were between 41-60 years and 16 
patients (14.8%) were 61 years or more. This shows that the disease was more 
prevalent between 41-60 years of age. 
       This observation was similar to WHO report which predicts that while the 
main increase in diabetes would be in the > 65 year age group in the developed 
countries, in India and developing countries the highest increase would occur in 
the age group of 45-65 year of age group.65  This observation is also similar to 
Kapur  et  al  , who reported that  maximum number  of  cases were diagnosed 
between  40  and  59  year  of  age  with  no  significant  difference  between  the 
genders.66 
GENDER DISTRIBUTION
      In the present study 40.7%(44 nos)  of the studied population were males 
and 59.3%(64 nos)  were females. Female to male ratio was 1.45:1. 
      This observation was similar to Arthur M. Michalek et al who reported that 
prevalence  of  diabetes  among  women  was  higher  than  in  men.67This  is  in 
contrast to Jali et al68 and Flatau E et al69  who reported that diabetes was more 
prevalent in men than in women. 
      Sample size in our study is too small. This might have affected the results. 
 DURATION OF DIABETES MELLITUS 
      In the present study, majority of cases that is 70.4% (76/108)  had duration 
of  diabetes up to 5 years, 18.5% (20/108) of patients had duration between 6-10 
years and 11.1% (120108) of patients had duration of illness more than  10 
years.Majority of people are in the age group between 41 to 60 yrs and have 
duration of disease less than 5 years. 
CO-MORBID DISEASES
       In  the  present  study,  50%(54/108)  of  the  studied  population   had 
hypertension.    L Tanow observed that  78% of IDDM patients  and 50% of 
NIDDM had  hypertension.70 Fuller H et al observed that the frequency of WHO 
defined hypertension was highest in NIDDM patients older than 53 years, being 
43% of male and 52% of females.71 Both these studies support our findings.
       Prevalence of CAD in general population in urban areas in India is 6.4%72. 
In the present study, 11.1% (12/108) of patients had Coronary Artery Disease 
almost  twice  that  of  in  general  population.   This  is  supported  by  two 
studies which concluded that  Type 2 diabetes  increases  relative risk 
of cardiovascular  disease two- to fourfold compared with the risk in 
the general population.73 ,74
FAMILY HISTORY  OF DIABETES MELLITUS
       In the present study, 38.9% (42nos) of patients had family history of 
Diabetes and the remaining 61.1% (66nos)  had no family history.
      This study is similar to that of  Tattersal and Fojans75 and Vishwanthan76 
.Vishwanthan et al conducted a study among 107 subjects. Out of 73 subjects 
who gave positive family history diabetes, 19 subjects (26%) later developed 
diabetes.
REGULARITY OF TREATMENT 
       In the present study, Out of 108 subjects of the study group, 6(5.6%)  were 
newly detected Diabetic patients. In the remaining , 75.9% (82/108) were on 
regular treatment and 18.5% (20/108) were irregular .  
      Asha et al  observed that  97%  of  type 2 diabetics were on antidiabetic 
agents and  most were using them irregularly.77  Kaur et al observed that oral 
anti  diabetic  drug  compliance  rate  was  62.9% in  diabetic  population.78  The 
difference in our study may be due to small sample size. 
 BMI
       Among the study population, 59.2%(64/108)  were overweight and obese; 
38.9%(42/108) had normal BMI.
       Mc Larty et al reported that prevalence of IGT in subjects of all age group 
increased with rising BMI.79  Yon Gik et  al  reported that  the prevalence of 
diabetes  mellitus  and  IGT  increased  with  rising  BMI  and  with  increase  in 
WHR.80 Both these studies support our findings. 
RETINOPATHY
      In the present study, 24.1% (26/108) patients had diabetic retinopathy  and 
rest 75.9% (82/108) had no retinopathy. This study was  almost  similar to that 
of  Marianne etal who observed that the prevalence of diabetic retinopathy in 
type 2 diabetes mellitus was 31.5%81 and  that of A.Southwell et a who found 
that prevalence of diabetic retinopathy was 15%.82
 
DYSLIPIDEMIA
       In the present study, 50% (54/108) of the study group had raised total 
cholesterol level; 84.24%(78/108)  had raised LDL-C level; 43.2% (40/108) had 
decreased  HDL-C  level  and  50%  (54/108)  had  hypertriglyceridemia.  This 
shows that the incidence of dyslipidemia is high in diabetics.
       Liao et al reported that patients who had diabetic glycaemic tolerance had 
more of intra-abdominal fat , higher  triglyceride levels, lower HDL cholesterol 
levels and higher blood pressure than those with Normal glucose tolerance.83 
A.Southwell  et  al  in  their  study  found  that  40%  of  the  diabetics  had 
hypercholesterolaemia.82   
HBA1C LEVEL
      In the present study,  51.9%( 56nos) had HbA1C level more than   8% and 
48.1% (52nos) had   level  HbA1C less than 8%. More than half of the diabetics 
had poor glycemic control.  Paolo fumelli  in his study of 562 diabetic patients 
found that all the patients had  level HbA1C greater than 8%.84 
ABNORMAL THYROID PROFILE
In  the  present  study,  13%  (14)  of  the  total  108  patients  with  diabetes 
mellitus had abnormal thyroid profile.
The present study is similar to Abdel-Rahman et al  who in his study of  908 
type 2  diabetic patients found that the prevalence of thyroid disease was 12.5%, 
6.6% of whom were newly diagnosed and 5.9% had known thyroid dysfunction. 
The prevalence of thyroid disease in the non diabetic control group was 6.6%.59 
Chubb et al  in a cross-sectional study of 420 patients with type  2 diabetes 
mellitus found that 8.6% of patients had subclinical hypothyroidism.64 
Smithson M J in his study found that  the prevalence of thyroid disease in 
the entire population of diabetic patients registered in the general practice was 
10.8%.  In  the  control  group  of  non  diabetics,  the  prevalence  was  6.6%.61 
D.H.akbar et al in their study of 100 type 2 diabetics found that the prevalence 
of thyroid dysfunction was 16% and in control groupof non diabetics, it was 
7%.85
       Zdrojewicz et al in their study of 75 diabetic patients found that there was 
no differences in thyroid gland function between patients with type 2 diabetes 
mellitus and non  diabetics.  This study contradicts our findings.62 
DISTRIBUTION OF THYROID ABNORMALITIES 
      In the present study, 11.1% (12) of the patients had report suggestive of 
sub clinical hypothyroidism and 1.9% (2) of the patients had report suggestive 
of sub clinical hyperthyroidism.
      This study was similar to Abdel-Rahman et al who in their study of 908 type 
2 diabetic patients found that 10.3% of patients had hypothyroidism (overt and 
sub  clinical)  and  1.7%  of  patients  had  hyperthyroidism  (overt  and  sub 
clinical).59  Smithson et al  in their study of 233 diabetes mellitus patients found 
that 11 patients were found to have undiagnosed thyroid disease, out of which 9 
were  having  hypothyroidism  (overt  and  sub  clinical)  and  2  were  having 
hyperthyroidism (overt and sub clinical).61 
       Celani MF et al in their study of  290 type 2 diabetes mellitus patients 
found that  91 patients(31.4%) had abnormal TSH concentrations  out of which 
48.3% had subclinical hypothyroidism, 24.2% had subclinicl hyperthyroidism, 
23.1% had overt hypothyroidism and 4.4% had overt hyperthyroidism.55     
      In the present study, diabetic patients, when compared with the control 
group of normal patients in Whickham Study86  and  a 20 years follow-up of 
whickham  survey by Vanderpump MP et  al87 shows that  the prevalence of 
altered thyroid profile in the study group is significant (p=0.0064). 
      The presence of altered thyroid profile in diabetic patients may be due to the 
fact that:    
• In euthyroid individuals with diabetes mellitus, the serum T3 levels, basal 
TSH levels and TSH response to thyrotropin releasing hormone (TRH) 
may all be strongly influenced by the glycemic status.41 
•  Poorly controlled diabetes may also result in impaired TSH response to 
TRH or loss of normal nocturnal TSH peak.43
• It may be related to older age of the type 2 DM patients.64
SIGNIFICANCE  OF  AGE   IN  PATIENTS  WITH  ABNORMAL 
THYROID PROFILE                 
       Among the patients  with abnormal thyroid profile, each 14.35% (2/14) of 
patients were found to be of age 61 and more and 40 or less. 71.4% (10/12) 
were found to be of age between 41-60 years. Though there is  difference, when 
Compared between patients with normal and abnormal thyroid profile it has no 
significance (p=0.987)              
      The present study findings contradict with that of Chubb et al who in their 
study found that age and anti – TPO status correlates with altered thyroid profile 
in diabetic patients.64  
      Vondra  et al in his study found that thyroid diseases in diabetic patients is 
2-3 times higher than in nondiabetic subjects; it raises with age, and is strongly 
influenced by female gender and autoimmune diabetes.  This also contradicts 
with our findings.58 
ANALYSIS  OF  SEX  DISTRIBUTION  IN  CASES  WITH ABNORMAL 
THYROID PROFILE           
        In the present study 85.7%(12/14) patients  were found to be female 
compared to 14.3% (2/12) male in the group with abnormal  thyroid profile. 
Compared between patients with normal and abnormal thyroid profile this is 
statistically  significant (p=0.031).
       Celani MF et al, Arthur M. Michalek et al and Abdel-Rahman et al in their 
study found that  the prevalence of thyroid dysfunction was significantly  higher 
in the female than in the male diabetic patients.55,67,59   
          Also Vondra et al and Cardoso et al found significant correlation between 
female gender and altered thyroid profile.58,88
SIGNIFICANCE OF TYPE OF TREATMENT  IN PATIENTS  WITH 
ABNORMAL  THYROID PROFILE
      Out of 14 patients with thyroid abnormality, 57.1%(8/14) were on OHA, 
14.3%(2/14) were on  Insulin and  28.6%(4/14) were on both OHA/Insulin. 
Compared with normal  thyroid profile  group it has no statistical significance 
(p=0.293) 
       The findings of our study are similar with Chubb et al , who in their study 
found that altered thyroid profile was associated with    anti – TPO status and 
age, but there was no independent associations with serum cholesterol, history 
of coronary heart disease, SHT, HbA1C or hypoglycaemic therapy.64  Celani MF 
et al in their study found that  the prevalence of abnormal thyroid function test 
results was significantly higher in insulin treated patients than in those receiving 
OHA. This contradicts with our study.55 
SIGNIFICANCE  OF  ASSOCIATED  SHT  AND  CAD  IN  PATIENTS 
WITH  ABNORMAL  THYROID PROFILE
       In the present study,  57.1%(8/14)  of  patients had hypertension in the 
group of 14 patients with abnormal thyroid profile whereas 42.9% (6 /14) of 
patients  had  no  hypertension.  This  finding  has  no  statistical  significance 
( p=0.567).    
        14.3% (2/14) were found to have CAD compared to 85.7% (12/14) without 
CAD in  patients  with  abnormal  thyroid  profile.  Compared between  patients 
with  normal  and  abnormal  thyroid  profile  this  finding  was  found  to  be 
insignificant (p=0.685). 
       The findings of our study are similar with Chubb et al  who in their study 
found that there was no independent association of altered thyroid profile with 
history of coronary heart disease and SHT.64  Muñoz Núñez et al  in a study of 
48 compensated diabetic patients,  found that there is a decrease of T3 in all 
diabetic patients,  this being more noticeable in diabetic females and diabetic 
patients with vascular disease.89 This contradicts with our study.  
ANALYSIS  OF  BMI  IN CASES  WITH  NORMAL  AND ABNORMAL 
THYROID  PROFILE
       Out of  14 patients with abnormal thyroid profile,   42.9%(6/14) were 
overweight and 28.6%(4/14) were obese. The mean BMI of the patients with 
altered thyroid profile was 27.30 Kg/m2 compared to 25.25 Kg/m2 in  patients 
with normal thyroid profile. There was no significant correlation  between BMI 
and abnormal thyroid profile(p=0.158). 
      Fan W et al observed in their study that  obese individuals have normal 
levels  of  thyroxine(T4)  and  thyroid  stimulating  hormone(TSH)  but, 
increased levels of triiodothyronin(T3) in a minority of subjects.90
      The findings contradict with Process et al who in their study  found that 
besides known parameters such as age and drugs, thyroid-function tests can also 
be altered by diabetes mellitus and obesity.55 
 ANALYSIS  OF  HbA1C LEVEL  IN  CASES  WITH  NORMAL  AND 
ABNORMAL THYROID PROFILE           
      Out of 14 patients with abnormal thyroid profile, 57.1%(8/14) had    HbA1C 
value  above 8% and the remaining(42.9%)  had HbA1C 8  or  less.  The  mean 
HbA1C level of the patients with abnormal thyroid profile was 9.29% compared 
to  8.67% in  the  patients  with  normal  thyroid  profile.  This  difference  is  not 
statistically significant(p=0.268). 
      The findings are similar to the studies  by Parr JH et al and Chubb et al  who 
found no correlation between changes in free thyroid hormone concentrations 
and  HbA1C level.63,64 
      Celani MF et al  in their study in 91diabetic  patients with altered thyroid 
profile found  that TSH level in serum decreased in subclinical hypothyroidism 
and  increased  in  subclinical  hyperthyroidism with  significant  fall  in  HbA1C 
level.  This contradicts  with our findings.
ANALYSIS  OF SERUM  LIPID PROFILE  IN CASES  WITH NORMAL 
AND ABNORMAL THYROID PROFILE
     Comparing the two groups the differences were not  statistically  significant. 
      S.A.P.Chubb et al in their substudy of Fremantle diabetes study found that 
there were strong association between TSH and lipid parameters with adverse 
cardiac  risks  at  low  insulin  sensitivity  that  were  absent  at  higher  insulin 
sensitivity.64 
      Bakker SJL et al also concluded the same in their study in non diabetic 
individuals with insulin resistance.91 Both these studies contradict our findings.
           
              Our study found that the prevalence of thyroid disease in diabetic 
population is more when compared to non diabetic patients.
           Age, duration of diabetes, type of treatment, history of hypertension or 
CAD, BMI, HbA1C level and serum  lipidprofile has no correlation with thyroid 
profile in type 2 diabetes mellitus but  there is significant correlation between 
female gender and abnormal thyroid profile.
                                              
 SUMMARY 
               This study  aimed at estimating the prevalence of thyroid dysfunction 
in  type 2 Diabetes mellitus  patients and also to find out it’s correlation with 
various risk factors.
                The study sample included 108 type 2 diabetic patients presented in 
the wards and outpatients department. Each patient was assessed clinically and 
by laboratory  investigations.
Primary  observations  regarding  thyroid  profile  in  patients  with  type  2 
diabetes mellitus
• In  the  present  study,  13%(14  nos)  of  patients  with  type  2  diabetes 
mellitus had abnormal thyroid profile. 
•  In  patients  with  abnormal   thyroid  profile(14nos),  most  common 
abnormality  was  subclinical  hypothyroidism(85.7%)  followed  by 
subclinical hyperthyroidism(14.3%).
• Our  study  showed  significant  correlation  between  abnormal  thyroid 
profile and gender, duration of diabetes and family history of diabetes. 
Binary logistic regression model analysis showed  significant association 
only with female gender.
• In  persons with abnormal thyroid profile, 85.7% were females and 14.3% 
were males.This  is  statistically  significant.  The  prevalence  of  thyroid 
abnormalities  is more common in females than in males.
• No significant correlation was found between altered thyroid profile and 
age,  type of treatment, SHT, CAD, BMI, HbA1C level and  serum lipid 
profile.
Additional observations in the study group of type 2 diabetes mellitus 
subjects:
• In  the  present  study,  patients  ranged  from  36  to  70  years  of  age. 
Maximum number of patients were in the age group between 41 to 60yrs 
(72.2%). 
• Majority (70.4% ) of patients were on OHA and  14.8% each  were on 
insulin and both OHA/Insulin.
• Majority( 75.9%) of  patients were on regular treatment and  18.5% were 
irregular.
•  30.9% patients   were  having  family  history  of  diabetes  mellitus  and 
61.1% had no family history.
•  The prevalence of  SHT (50%)  and  CAD (11.1%)  were higher among 
diabetic population.
• Significant number of patients (24.1%) had diabetic retinopathy.
• Majority  (59.2%) of the diabetic patients   were overweight and obese. 
•  51.9% had HbA1C level more than  8% and   48.1%  had  HbA1C level 
less  than  8%  showing  that  more  than  half   of  the  patiens  had  poor 
glycaemic control.
•  50% of the patients had raised total cholesterol level, 84.24% had raised 
LDL cholesterol level, 43.25% had decreased HDL cholesterol level and 
50% had raised  Triglyceride level  showing that  majority  of  diabetics 
have dyslipidemia.
                                        CONCLUSION
•    Prevalence  of  thyroid  dysfunction  is  more  common among type  2 
diabetes mellitus  patients than in general population.
•    Prevalence  of  thyroid  dysfunction  in  patients  with  type  2  diabetes 
mellitus  is higher in females than in males 
•  There is no significant correlation between  Age,  Duration of diabetes, 
Family history of diabetes, type of treatment, SHT, CAD, BMI, HbA1C 
level and  serum lipid profile.
•   Routine screening  for thyroid  dysfunction in type 2 diabetes mellitus 
patients may be justified  especially in females because the progression to 
overt  thyroid  dysfunction  is  associated  with  significant  morbidity 
including the adverse  effects  on glycemic control,  lipid  profile,   bone 
mineral density and cardiovascular events.
                                        LIMITATIONS
•    Study population was small.
•   Associated thyroid autoimmunity was not evaluated due to constraints. 
So it was not able to refine the  spectrum of thyroid dysfunction in type 2 
diabetics.
•  Follow up study  was  not done. So the natural history of subclinical 
thyroid dysfunction and  it’s  effect on various parameters could not be 
assessed.
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                           RECOMMENDATIONS
• Biochemical tests of thyroid functions are readily available and relatively 
inexpensive. So, a baseline thyroid function test  to be done in all type 2 
dibetic patients at first visit especially in females.
• Longitudinal  studies  are  needed  to  find  out  the  incidence  of  thyroid 
dysfunction in type 2 diabetes mellitus patients and to determine the need 
of regular screening for thyroid dysfunction during follow up and it’s cost 
effectiveness.
•  Follow up thyroid function test to be done  to assess  the progression of 
subclinical thyroid dysfunction in type 2 diabetics because of associated 
morbidity of overt thyroid dysfunction in these patients. 
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PROFORMA
STUDY OF THYROID PROFILE IN TYPE 2 DIABETES MELLITUS
S.No. Reg. No. (OPD/Ward)
Name: Age/Sex
Address:
Occupation Religion SES
Presenting Complaints:
Tiredness Dry Skin                 muscle cramps 
Decreased sweating                                Insomnia 
Somnolence
Poor Appetite Myalgia/Arthralgia
Weight Gain/Weight Loss Breathlessness
Cold Intolerance Swollen Limb
Constipation Paresthesia
Change in Voice Impaired Hearing
Menstrual Irregularities Infertility/Abortion
Libido Poor Memory /Difficulty 
                                                       inConcentration 
                                                      
Behavioral Changes Tremors
Palpitation irritability
PAST HISTORY
HT/ Others
IHD
DIABETIC HISTORY
♦ Known Diabetic Since
♦ Whether on Regular Rx or not
♦ It Rx then what is the treatment on which the patient is
♦ Whether Diabetic Status Under Control
♦ When was the last Blood test done results
FAMILY HISTORY
Hypertension Diabetes Mellitus IHD
Hypothyroidism Goiter
PERSONAL HISTORY
Diet Menstrual History 
Addiction: Tobacco Chewing/Smoking/Both
Alcohol-Occasional/Daily/Moderate/Heavy
TREATMENT HISTORY
GENERAL EXAMINATION
Height Weight BMI Pallor 
Icterus Xanthelasma Madarosis 
Pulse Peripheral Pulsation 
B. P. Lying 
Standing 
Skin : Cold/Coarse/Moist/Dry/Yellowish Discoloration 
Edema Facial Puffiness Alopecia Tongue 
Thyroid Gland : Normal/Enlarged 
SYSTEMIC EXAMINATION: 
C. V. S. 
R. S. 
P/A
C. N. S. 
INVESTIGATIONS: 
Hb (gm%) TLC DLC P L E M                          
                                      B
ESR
FBS 
PPBS HbA1C 
 
B. Urea S. Creatinine 
ECG                         CXR
Thyroid Profile: FT3 FT4 TSH
Lipid Profile 
         TC TG HDL-C               LDL-C 
Urine spot PCR:
Fundus :
Peripheral neuropathy:
REMARK:  
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